Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | APEX1 | P27695 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769736 | 1.00 | L3MBTL1 (0.54) | L3MBTL1ACACBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15979306 | 0.90 | L3MBTL1 (0.54) | L3MBTL1ACACBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15449627 | 0.88 | L3MBTL1 (0.61) | L3MBTL1ACACBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14769737 | 0.86 | L3MBTL1 (0.51) | L3MBTL1ACACBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8686037 | 0.86 | L3MBTL1 (0.68) | L3MBTL1ACACBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14773341 | 0.83 | KMT2A (0.68) | L3MBTL1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL16726906 | 0.82 | L3MBTL1 (0.49) | L3MBTL1ACACBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18269843 | 0.81 | MEN1 (0.47) | L3MBTL1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL14769735 | 0.79 | LMNA (0.49) | L3MBTL1ACACBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12929400 | 0.79 | SMN1; SMN2 (0.62) | MEN1KMT2ASMN1; SMN2LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | L3MBTL1 762/4885ACACB 312/4885MEN1 4221/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | L3MBTL1 762/4885ACACB 312/4885MEN1 4221/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | L3MBTL1 3171/4885ACACB 949/4885MEN1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.